FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894981552> ?p ?o ?g. }

• W2894981552 endingPage "2563" @default.
• W2894981552 startingPage "2555" @default.
• W2894981552 abstract "Abstract It is important to have an effective therapy for patients with multiple myeloma (MM) at first relapse, particularly if an autologous stem cell transplant (ASCT) is considered at this stage. This multicenter, phase 2 trial evaluated the efficacy and safety of weekly oral pomalidomide-cyclophosphamide-dexamethasone (PCD) in patients with MM in first relapse after treatment with lenalidomide-bortezomib-dexamethasone (RVD). All patients had received RVD as induction and consolidation therapy, plus lenalidomide maintenance for 1 year (arm A). Half had also received an ASCT after induction (arm B). At MM relapse, all patients received 4 oral cycles of pomalidomide 4 mg (days 1-21), cyclophosphamide 300 mg (days 1, 8, 15, and 22), and dexamethasone 40 mg (days 1-4 and days 15-18 of a 28-day cycle; PCD). Responding patients in arm A underwent ASCT and received 2 additional cycles of PCD, whereas those in arm B received 5 cycles of PCD. All patients received pomalidomide-dexamethasone maintenance until disease progression. Primary end point was partial remission or better after the initial 4 cycles of PCD. Responses were obtained in 82/97 (85%) patients evaluated: complete remission (n = 1; 1%), very good partial remission (n = 32; 33%), and partial remission (n = 49; 51%). Three patients (3%) had stable disease, and 6 (6%) had disease progression (6 response failures). Forty-five (94%) of the 48 patients in arm A underwent planned ASCT. PCD was effective therapy after first relapse with RVD. After 4 cycles, the rate of partial remission or better was 85%, and 94% of planned ASCTs were performed. Toxicity was mostly hematologic and manageable. This trial was registered at www.clinicaltrials.gov as #NCT02244125." @default.
• W2894981552 created "2018-10-12" @default.
• W2894981552 creator A5000455173 @default.
• W2894981552 creator A5000761302 @default.
• W2894981552 creator A5003294000 @default.
• W2894981552 creator A5006671522 @default.
• W2894981552 creator A5011827756 @default.
• W2894981552 creator A5020056942 @default.
• W2894981552 creator A5020665054 @default.
• W2894981552 creator A5020996390 @default.
• W2894981552 creator A5025404578 @default.
• W2894981552 creator A5025996929 @default.
• W2894981552 creator A5026625329 @default.
• W2894981552 creator A5026970655 @default.
• W2894981552 creator A5029600580 @default.
• W2894981552 creator A5031019986 @default.
• W2894981552 creator A5037888163 @default.
• W2894981552 creator A5038965613 @default.
• W2894981552 creator A5044238802 @default.
• W2894981552 creator A5045552922 @default.
• W2894981552 creator A5045605051 @default.
• W2894981552 creator A5048560248 @default.
• W2894981552 creator A5059170395 @default.
• W2894981552 creator A5059590275 @default.
• W2894981552 creator A5060698923 @default.
• W2894981552 creator A5064803767 @default.
• W2894981552 creator A5067096291 @default.
• W2894981552 creator A5069447323 @default.
• W2894981552 creator A5069745915 @default.
• W2894981552 creator A5071589084 @default.
• W2894981552 creator A5073015935 @default.
• W2894981552 creator A5077081397 @default.
• W2894981552 creator A5079283579 @default.
• W2894981552 creator A5079604805 @default.
• W2894981552 creator A5079897574 @default.
• W2894981552 creator A5082698003 @default.
• W2894981552 creator A5082733021 @default.
• W2894981552 creator A5088332415 @default.
• W2894981552 creator A5089853890 @default.
• W2894981552 date "2018-12-13" @default.
• W2894981552 modified "2023-10-18" @default.
• W2894981552 title "Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma" @default.
• W2894981552 cites W1984254136 @default.
• W2894981552 cites W1985864219 @default.
• W2894981552 cites W1992470642 @default.
• W2894981552 cites W2044436186 @default.
• W2894981552 cites W2048056023 @default.
• W2894981552 cites W2059294866 @default.
• W2894981552 cites W2059876129 @default.
• W2894981552 cites W2066800926 @default.
• W2894981552 cites W2091773528 @default.
• W2894981552 cites W2094933328 @default.
• W2894981552 cites W2102939102 @default.
• W2894981552 cites W2120113475 @default.
• W2894981552 cites W2123159083 @default.
• W2894981552 cites W2133739087 @default.
• W2894981552 cites W2136541422 @default.
• W2894981552 cites W2146646005 @default.
• W2894981552 cites W2169965478 @default.
• W2894981552 cites W2193716145 @default.
• W2894981552 cites W2201190784 @default.
• W2894981552 cites W2302708051 @default.
• W2894981552 cites W2326706351 @default.
• W2894981552 cites W2334764571 @default.
• W2894981552 cites W2343386476 @default.
• W2894981552 cites W2394652810 @default.
• W2894981552 cites W2512106959 @default.
• W2894981552 cites W2522419283 @default.
• W2894981552 cites W2528329272 @default.
• W2894981552 cites W2567188480 @default.
• W2894981552 cites W2604776612 @default.
• W2894981552 cites W2625253716 @default.
• W2894981552 cites W2731606591 @default.
• W2894981552 cites W2776818949 @default.
• W2894981552 cites W2979734599 @default.
• W2894981552 cites W4206651001 @default.
• W2894981552 doi "https://doi.org/10.1182/blood-2018-07-863829" @default.
• W2894981552 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30282798" @default.
• W2894981552 hasPublicationYear "2018" @default.
• W2894981552 type Work @default.
• W2894981552 sameAs 2894981552 @default.
• W2894981552 citedByCount "51" @default.
• W2894981552 countsByYear W28949815522019 @default.
• W2894981552 countsByYear W28949815522020 @default.
• W2894981552 countsByYear W28949815522021 @default.
• W2894981552 countsByYear W28949815522022 @default.
• W2894981552 countsByYear W28949815522023 @default.
• W2894981552 crossrefType "journal-article" @default.
• W2894981552 hasAuthorship W2894981552A5000455173 @default.
• W2894981552 hasAuthorship W2894981552A5000761302 @default.
• W2894981552 hasAuthorship W2894981552A5003294000 @default.
• W2894981552 hasAuthorship W2894981552A5006671522 @default.
• W2894981552 hasAuthorship W2894981552A5011827756 @default.
• W2894981552 hasAuthorship W2894981552A5020056942 @default.
• W2894981552 hasAuthorship W2894981552A5020665054 @default.
• W2894981552 hasAuthorship W2894981552A5020996390 @default.
• W2894981552 hasAuthorship W2894981552A5025404578 @default.
• W2894981552 hasAuthorship W2894981552A5025996929 @default.

• next